Skip to main content

ADPKD clinical trials at UCSF
1 in progress, 1 open to new patients

  • Tesevatinib in Subjects With ADPKD

    open to eligible people ages 18–60

    The goal of the study is to compare and evaluate safety and efficacy of tesevatinib 50mg versus placebo in patients with ADPKD.

    San Francisco, California and other locations